Public trading strategy
Eli Lilly's obesity drug data impresses analysts — jump back into the weight-los
Thesis
The obesity drug market is shaping up to be one of the biggest opportunities in healthcare history. Eli Lilly just confirmed to Wall Street that its drug portfolio is robust and not reliant on just one product. With presentations at a major conference easing any competitive fears, the stock looks ready to continue its long-term climb higher.
Strategy approach
Build a rule-based strategy that enters long LLY on the daily chart when the price pulls back to the 21-day EMA and the RSI(14) bounces off the 40 level. Exit the position if the price closes below the 50-day EMA, or set a 6% trailing stop.
Markets and timeframes
LLY1D